Halozyme Therapeutics (HALO) Tops Q2 EPS by 30c ; Offers Guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $69.31 +1.11%
Revenue Growth %: +23.1%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +23.1%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $1.54, $0.30 better than the analyst estimate of $1.24. Revenue for the quarter came in at $326 million versus the consensus estimate of $286.01 million.
GUIDANCE:
Halozyme Therapeutics sees FY2025 EPS of $6.00-$6.40, versus the consensus of $5.40. Halozyme Therapeutics sees FY2025 revenue of $1.27-1.35 billion, versus the consensus of $1.25 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- Lockheed, RTX, Boeing, L3Harris expected to meet with Trump - WSJ
- United Airlines flies first Starlink-equipped widebody on transatlantic route
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
